Obefazimod (ABX464) in Ulcerative Colitis

Obefazimod, also known as ABX464, is a first-in-class small molecule with a novel mechanism of action specifically designed to treat moderate-to-severe ulcerative colitis (UC). Below is a detailed overview of its features, mechanism, clinical trials, and safety profile:

### **Mechanism of Action**

Obefazimod works by upregulating **miR-124**, a naturally occurring anti-inflammatory microRNA. This upregulation leads to the downregulation of key pro-inflammatory cytokines such as **TNF-α**, **IL-6**, and **IL-17**, which are heavily involved in the inflammatory process of UC. By modulating these cytokines, Obefazimod acts as a natural brake on inflammation, offering a non-immunosuppressive approach to managing UC. This upstream mechanism is unique and differentiates Obefazimod from other therapies in the UC treatment landscape.

### **Clinical Trials**

#### **Phase 2b Trials**

• **Efficacy:** Obefazimod demonstrated significant efficacy in achieving clinical remission in patients with moderate-to-severe UC.
• **Safety:** The trials established the drug's safety profile, paving the way for further investigation in larger Phase 3 trials.

#### **Phase 3 Trials (ABTECT-1 and ABTECT-2)**

• **Primary Endpoint:** Obefazimod achieved the FDA’s primary endpoint of clinical remission at Week 8, particularly with the 50 mg dose.
• **Optimal Dose:** The 50 mg dose emerged as the preferred option due to its effectiveness and better tolerability compared to higher doses.

### **Long-Term Safety & Efficacy**

In 2-year open-label extension studies:

• Patients who initially received 100 mg and later switched to the 50 mg dose maintained **clinical remission** and **mucosal healing** over the long term.
• This suggests that the lower dose is effective for sustained disease control and maintenance therapy.

### **Safety Profile**

• **Favorable Tolerability:** The 50 mg dose was better tolerated, with fewer adverse events compared to the 100 mg dose. This makes it the preferred long-term maintenance dose.
• **Non-Immunosuppressive:** Unlike conventional immunosuppressive therapies, Obefazimod’s mechanism avoids the risks associated with widespread immune suppression, such as infections or malignancies.

### **Unique Positioning**

Obefazimod represents a **differentiated treatment option** in the UC landscape due to its:

1. **Novel Mechanism:** It targets inflammation upstream via miR-124 regulation rather than suppressing the immune system directly.

2. **First-in-Class Status:** It is the first therapy of its kind, offering a new pathway for managing moderate-to-severe UC.

3. **Non-Immunosuppressive Nature:** This makes it an attractive option for patients seeking alternatives to traditional immunosuppressive or biologic therapies.

### **Conclusion**

Obefazimod (ABX464) is a promising therapeutic option for patients with moderate-to-severe UC. Its unique mechanism of action, favorable safety profile, and demonstrated efficacy in clinical trials position it as a potential game-changer in the UC treatment landscape. The drug’s ability to provide long-term remission and mucosal healing without immunosuppression makes it a compelling choice for both induction and maintenance therapy.